Coherus Oncology, Inc. Operating Cash Flow
Coherus Oncology, Inc. (CHRS) reported Operating Cash Flow of -$119.98 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$62.09M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$57.89M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$19.72M, a 168.92% decline year-over-year.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$46.34M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$138.51M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$20.44M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$241.12M.
- Coherus Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2021 was -$37.43M, a 124.28% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$62.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$119.98M 10-Q · filed 2026-08-05 | -$139.69M derived: sum of 3 quarters · filed 2026-08-05 | -$186.03M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$57.89M 10-Q · filed 2026-05-11 | -$77.60M derived: sum of 2 quarters · filed 2026-05-11 | -$123.94M derived: sum of 3 quarters · filed 2026-05-11 | -$170.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$19.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$66.06M derived: sum of 2 quarters · filed 2026-03-09 | -$112.69M derived: sum of 3 quarters · filed 2026-08-05 | -$138.51M 10-K · filed 2026-03-09 |
| 2025-09-30 | -$46.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$92.97M derived: sum of 2 quarters · filed 2026-08-05 | -$118.80M 10-Q · filed 2025-11-06 | -$90.19M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$46.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$72.46M 10-Q · filed 2026-08-05 | -$43.85M derived: sum of 3 quarters · filed 2026-08-05 | -$105.87M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$25.83M 10-Q · filed 2026-05-11 | $2.78M derived: sum of 2 quarters · filed 2026-05-11 | -$59.23M derived: sum of 3 quarters · filed 2026-05-11 | $500.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $28.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$33.41M derived: sum of 2 quarters · filed 2026-03-09 | $26.33M derived: sum of 3 quarters · filed 2026-03-09 | -$20.44M 10-K · filed 2026-03-09 |
| 2024-09-30 | -$62.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$2.28M derived: sum of 2 quarters · filed 2025-11-06 | -$49.05M 10-Q · filed 2025-11-06 | -$61.98M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $59.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $12.97M 10-Q · filed 2025-08-07 | $31.00K derived: sum of 3 quarters · filed 2025-11-13 | -$54.27M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-03-31 | -$46.77M 10-Q · filed 2025-05-12 | -$59.70M derived: sum of 2 quarters · filed 2025-11-13 | -$114.00M derived: sum of 3 quarters · filed 2025-11-13 | -$152.92M derived: sum of 4 quarters · filed 2025-11-13 |
| 2023-12-31 | -$12.94M derived: 8-K 12 month − 10-Q 9 month · filed 2025-11-13 | -$67.24M derived: sum of 2 quarters · filed 2025-11-13 | -$106.15M derived: sum of 3 quarters · filed 2025-11-13 | -$174.88M 8-K · filed 2025-11-13 |
| 2023-09-30 | -$54.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$93.22M derived: sum of 2 quarters · filed 2024-11-06 | -$161.95M 10-Q · filed 2024-11-06 | -$261.90M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | -$38.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$107.65M 10-Q · filed 2024-08-08 | -$207.60M derived: sum of 3 quarters · filed 2025-03-17 | -$244.69M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | -$68.73M 10-Q · filed 2024-05-09 | -$168.69M derived: sum of 2 quarters · filed 2025-03-17 | -$205.77M derived: sum of 3 quarters · filed 2025-03-17 | -$255.81M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | -$99.95M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$137.04M derived: sum of 2 quarters · filed 2025-03-17 | -$187.08M derived: sum of 3 quarters · filed 2025-03-17 | -$241.12M 10-K · filed 2025-03-17 |
| 2022-09-30 | -$37.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$87.13M derived: sum of 2 quarters · filed 2023-11-06 | -$141.17M 10-Q · filed 2023-11-06 | -$193.49M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-06-30 | -$50.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | -$104.08M 10-Q · filed 2023-08-02 | -$156.40M derived: sum of 3 quarters · filed 2024-03-15 | -$142.69M derived: sum of 4 quarters · filed 2024-03-15 |
| 2022-03-31 | -$54.05M 10-Q · filed 2023-05-08 | -$106.37M derived: sum of 2 quarters · filed 2024-03-15 | -$92.66M derived: sum of 3 quarters · filed 2024-03-15 | -$92.84M derived: sum of 4 quarters · filed 2024-03-15 |
| 2021-12-31 | -$52.32M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$38.61M derived: sum of 2 quarters · filed 2024-03-15 | -$38.80M derived: sum of 3 quarters · filed 2024-03-15 | -$37.43M 10-K · filed 2024-03-15 |
| 2021-09-30 | $13.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $13.52M derived: sum of 2 quarters · filed 2022-11-08 | $14.89M 10-Q · filed 2022-11-08 | $48.01M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-06-30 | -$188.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.18M 10-Q · filed 2022-08-04 | $34.30M derived: sum of 3 quarters · filed 2023-03-06 | $81.66M derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-03-31 | $1.37M 10-Q · filed 2022-05-05 | $34.49M derived: sum of 2 quarters · filed 2023-03-06 | $81.84M derived: sum of 3 quarters · filed 2023-03-06 | $142.03M derived: sum of 4 quarters · filed 2023-03-06 |
| 2020-12-31 | $33.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $80.48M derived: sum of 2 quarters · filed 2023-03-06 | $140.67M derived: sum of 3 quarters · filed 2023-03-06 | $154.15M 10-K · filed 2023-03-06 |
| 2020-09-30 | $47.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $107.54M derived: sum of 2 quarters · filed 2021-11-08 | $121.02M 10-Q · filed 2021-11-08 | $138.73M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-06-30 | $60.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $73.67M 10-Q · filed 2021-08-05 | $91.38M derived: sum of 3 quarters · filed 2022-02-23 | $146.33M derived: sum of 4 quarters · filed 2022-02-23 |
| 2020-03-31 | $13.48M 10-Q · filed 2021-05-06 | $31.19M derived: sum of 2 quarters · filed 2022-02-23 | $86.14M derived: sum of 3 quarters · filed 2022-02-23 | $98.81M derived: sum of 4 quarters · filed 2022-02-23 |
| 2019-12-31 | $17.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $72.66M derived: sum of 2 quarters · filed 2022-02-23 | $85.34M derived: sum of 3 quarters · filed 2022-02-23 | $28.36M 10-K · filed 2022-02-23 |
| 2019-09-30 | $54.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $67.63M derived: sum of 2 quarters · filed 2020-11-05 | $10.64M 10-Q · filed 2020-11-05 | -$36.72M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $12.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$44.31M 10-Q · filed 2020-08-06 | -$91.67M derived: sum of 3 quarters · filed 2021-02-25 | -$134.46M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | -$56.98M 10-Q · filed 2020-05-07 | -$104.35M derived: sum of 2 quarters · filed 2021-02-25 | -$147.13M derived: sum of 3 quarters · filed 2021-02-25 | -$182.66M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | -$47.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$90.15M derived: sum of 2 quarters · filed 2021-02-25 | -$125.68M derived: sum of 3 quarters · filed 2021-02-25 | -$159.27M 10-K · filed 2021-02-25 |
| 2018-09-30 | -$42.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$78.32M derived: sum of 2 quarters · filed 2019-11-08 | -$111.90M 10-Q · filed 2019-11-08 | -$141.82M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | -$35.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$69.11M 10-Q · filed 2019-08-05 | -$99.04M derived: sum of 3 quarters · filed 2020-02-27 | -$140.55M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | -$33.58M 10-Q · filed 2019-05-09 | -$63.51M derived: sum of 2 quarters · filed 2020-02-27 | -$105.02M derived: sum of 3 quarters · filed 2020-02-27 | |
| 2017-12-31 | -$29.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$71.44M derived: sum of 2 quarters · filed 2020-02-27 | -$200.29M 10-K · filed 2020-02-27 | |
| 2017-09-30 | -$41.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$170.36M 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | -$128.85M 10-Q · filed 2018-08-08 | |||
| 2016-12-31 | -$252.54M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |